Adalimumab-Ryvk Kit shortage
Adalimumab-Ryvk Kit is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 25, 2026.
Teva is stopping production of the Adalimumab-Ryvk Kit, and this change may be permanent. Simlandi, a related adalimumab kit, is still listed by other manufacturers not reporting a shortage.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Adalimumab-Ryvk Kit. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Nov 13, 2025Currently in shortage1 of 1 product affected.
-
Nov 13, 2025First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 1 NDC click to expand
| Status | NDC / product | Strength / size | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Simlandi, Kit, Kit (NDC 51759-523-21) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Adalimumab-Ryvk Kit — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Adalimumab-Ryvk Kit? options further down this page.
Why is Adalimumab-Ryvk Kit in shortage?
Teva Pharmaceuticals has reported to the FDA that they are permanently stopping the manufacture of their adalimumab-rvyk kit (Simlandi). This means this specific product from Teva will no longer be made going forward.
As for the specific reason why Teva made this decision, they did not share a public explanation with the FDA — just that they are discontinuing manufacturing of this product. It's worth knowing that this report only covers Teva's version of this product, so it doesn't necessarily mean adalimumab is unavailable from every manufacturer out there.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Adalimumab-Ryvk Kit, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Adalimumab-Ryvk Kit?
Adalimumab-Ryvk Kit is currently listed on the FDA drug-shortage list. The maker that filed this report, Teva Pharmaceuticals USA, Inc., has marked its product (Simlandi Kit) as to be discontinued, which means this particular supply problem may be permanent rather than temporary.
The reported reason is the discontinuation of the manufacture of the drug. Because this is a planned discontinuation, the right next step is a conversation with your prescriber or pharmacist so you can plan ahead calmly. Please keep in mind this report reflects only the manufacturer who filed it — the same medicine may still be supplied by other makers.
Here is what I'd suggest, in order:
- Do not stop, skip, or change your doses on your own — keep taking your medicine as prescribed while you sort out supply.
- Ask your pharmacy whether they can source the same medicine from another maker. Our records show the same ingredient is also listed under Simlandi from A-S Medication Solutions, Simlandi from Teva, and Adalimumab-Ryvk from Quallent Pharmaceuticals Health LLC — though these may not be in local stock.
- If your product cannot be found, ask your prescriber or pharmacist about a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Adalimumab-Ryvk Kit?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Adalimumab-Ryvk Kit is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Simlandi | Kit · Subcutaneous | A-S Medication Solutions | 50090-7718-00 | |
| Simlandi | Kit | Teva Pharmaceuticals USA, Inc. | 51759-0274-17 | |
| Adalimumab-Ryvk | Kit · Subcutaneous | Quallent Pharmaceuticals Health LLC | 82009-0156-22 |
Therapeutic equivalents & pricing 8 productsclick to expand
Orange Book–rated equivalents of the affected strengths / sizes, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Simlandi | Teva | 2 kits | $478.649 | — | Availability likely |
| Simlandi | Teva | 1 kit | — | — | FDA listed |
| Adalimumab-ryvk | Teva | 1 kit | — | — | FDA listed |
| Simlandi | Teva | 2 kits | — | — | FDA listed |
| Simlandi | Teva | 1 kit | — | — | FDA listed |
| Adalimumab-ryvk | Teva | 2 kits | — | — | FDA listed |
| Adalimumab-ryvk | Teva | 2 kits | — | — | FDA listed |
| Adalimumab-ryvk | Teva | 1 kit | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Adalimumab-Ryvk Kit — that fall in the same broad treatment class (anti-inflammatory tumor necrosis factor inhibitor) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other rheumatology shortages
Adalimumab-Ryvk Kit shortage FAQs
Is Adalimumab-Ryvk Kit in shortage?
Which products are affected?
When will Adalimumab-Ryvk Kit be available again?
Can I still get Adalimumab-Ryvk Kit somewhere?
What should I do if I take Adalimumab-Ryvk Kit?
Still have a question about the Adalimumab-Ryvk Kit shortage?
Ask a pharmacist about this shortage →View Adalimumab-Ryvk Kit on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.